Forecast Track Record
A complete, leakage-free ledger of forecasts recorded before each regulatory decision. Pending calls remain visible and records are never rewritten after outcomes are known.
Prospective Forecast Ledger
One frozen call per program and FDA target date. Resolved calls take precedence over later pending forecasts.
6 unique decisions resolved · 5 correct · 31 pending · 83% accuracy
Ulixacaltamide
PRAX · PDUFA Target Action Date Set
Frozen Oct 12, 2026
88% approval
Pending
Jan 29, 2027
Relutrigine
PRAX · Relutrigine PDUFA target action date (extended)
Frozen Oct 12, 2026
85% approval
Pending
Dec 27, 2026
Zanzalintinib + Atezolizumab
EXEL · Target action date for zanzalintinib + atezolizumab
Frozen Sep 17, 2026
88% approval
Pending
Dec 3, 2026
Vebevirgene
BBIO · Prescription Drug User Fee Act Target Action Date
Frozen Sep 28, 2026
92% approval
Pending
Nov 27, 2026
Deramiocel
CAPR · Extended PDUFA Target Action Date
Frozen Sep 26, 2026
55% approval
Pending
Nov 22, 2026
Ivonescimab
SMMT · Target Action Date for EGFR-mutated NSCLC BLA
Frozen Sep 26, 2026
78% approval
Pending
Nov 14, 2026
Mitapivat
AGIO · FDA Target Action Date under Priority Review
Frozen Oct 12, 2026
45% approval
Pending
Nov 1, 2026
INO-3107
INO · FDA PDUFA decision — INO-3107 for adult RRP
Frozen Oct 12, 2026
35% approval
Pending
Oct 30, 2026
Enspryng
RHHBY · FDA PDUFA decision — Enspryng for TED
Frozen Oct 12, 2026
55% approval
Pending
Oct 15, 2026
ifinatamab deruxtecan
DSKYF · FDA Action Date
Frozen Sep 17, 2026
82% approval
Discontinued · MISS
Oct 10, 2026
Tecentriq Hybreza
RHHBY · FDA PDUFA decision — Tecentriq / Hybreza adjuvant colon cancer
Frozen Oct 8, 2026
85% approval
Approved · HIT
Oct 9, 2026
WELIREG + LENVIMA
MRK · Target action date for sNDA
Frozen Sep 17, 2026
88% approval
Approved · HIT
Oct 4, 2026
Zilurgisertib
MIRM · PDUFA Target Action Date
Frozen Sep 14, 2026
88% approval
Approved · HIT
Sep 26, 2026